Logo image of DRTS

ALPHA TAU MEDICAL LTD (DRTS) Stock Fundamental Analysis

USA - NASDAQ:DRTS - IL0011839383 - Common Stock

3.97 USD
+0.03 (+0.76%)
Last: 11/12/2025, 4:51:31 PM
3.87 USD
-0.1 (-2.52%)
After Hours: 11/12/2025, 4:51:31 PM
Fundamental Rating

2

Overall DRTS gets a fundamental rating of 2 out of 10. We evaluated DRTS against 189 industry peers in the Health Care Equipment & Supplies industry. DRTS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. DRTS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DRTS has reported negative net income.
In the past year DRTS has reported a negative cash flow from operations.
In the past 5 years DRTS always reported negative net income.
In the past 5 years DRTS always reported negative operating cash flow.
DRTS Yearly Net Income VS EBIT VS OCF VS FCFDRTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

DRTS has a Return On Assets (-31.73%) which is in line with its industry peers.
DRTS's Return On Equity of -40.64% is in line compared to the rest of the industry. DRTS outperforms 53.44% of its industry peers.
Industry RankSector Rank
ROA -31.73%
ROE -40.64%
ROIC N/A
ROA(3y)-30.7%
ROA(5y)-34.69%
ROE(3y)-39.04%
ROE(5y)-55.73%
ROIC(3y)N/A
ROIC(5y)N/A
DRTS Yearly ROA, ROE, ROICDRTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DRTS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DRTS Yearly Profit, Operating, Gross MarginsDRTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for DRTS has been increased compared to 1 year ago.
The number of shares outstanding for DRTS has been increased compared to 5 years ago.
The debt/assets ratio for DRTS is higher compared to a year ago.
DRTS Yearly Shares OutstandingDRTS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
DRTS Yearly Total Debt VS Total AssetsDRTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

DRTS has an Altman-Z score of 5.89. This indicates that DRTS is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of DRTS (5.89) is better than 80.95% of its industry peers.
DRTS has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
DRTS's Debt to Equity ratio of 0.07 is fine compared to the rest of the industry. DRTS outperforms 65.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 5.89
ROIC/WACCN/A
WACCN/A
DRTS Yearly LT Debt VS Equity VS FCFDRTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 10.52 indicates that DRTS has no problem at all paying its short term obligations.
With an excellent Current ratio value of 10.52, DRTS belongs to the best of the industry, outperforming 94.18% of the companies in the same industry.
A Quick Ratio of 10.52 indicates that DRTS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 10.52, DRTS belongs to the top of the industry, outperforming 94.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.52
Quick Ratio 10.52
DRTS Yearly Current Assets VS Current LiabilitesDRTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

DRTS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.00%.
EPS 1Y (TTM)-20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 27.43% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-10.27%
EPS Next 2Y7.55%
EPS Next 3Y32.46%
EPS Next 5Y27.43%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DRTS Yearly Revenue VS EstimatesDRTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
DRTS Yearly EPS VS EstimatesDRTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DRTS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DRTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRTS Price Earnings VS Forward Price EarningsDRTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRTS Per share dataDRTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

DRTS's earnings are expected to grow with 32.46% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.55%
EPS Next 3Y32.46%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DRTS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALPHA TAU MEDICAL LTD

NASDAQ:DRTS (11/12/2025, 4:51:31 PM)

After market: 3.87 -0.1 (-2.52%)

3.97

+0.03 (+0.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-25 2025-11-25/amc
Inst Owners2.27%
Inst Owner Change1.86%
Ins Owners16.2%
Ins Owner ChangeN/A
Market Cap337.61M
Revenue(TTM)N/A
Net Income(TTM)-35.20M
Analysts86
Price Target8.67 (118.39%)
Short Float %0.16%
Short Ratio1.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2%
Min EPS beat(2)-11.55%
Max EPS beat(2)7.55%
EPS beat(4)2
Avg EPS beat(4)2.35%
Min EPS beat(4)-11.55%
Max EPS beat(4)18.47%
EPS beat(8)6
Avg EPS beat(8)11.12%
EPS beat(12)9
Avg EPS beat(12)17.76%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.99%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.9
P/tB 3.9
EV/EBITDA N/A
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0
BVpS1.02
TBVpS1.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.73%
ROE -40.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.7%
ROA(5y)-34.69%
ROE(3y)-39.04%
ROE(5y)-55.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 495.91%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.52
Quick Ratio 10.52
Altman-Z 5.89
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)296.97%
Cap/Depr(5y)1091.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
EPS Next Y-10.27%
EPS Next 2Y7.55%
EPS Next 3Y32.46%
EPS Next 5Y27.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.72%
EBIT Next 3Y65.5%
EBIT Next 5YN/A
FCF growth 1Y-39.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.9%
OCF growth 3YN/A
OCF growth 5YN/A

ALPHA TAU MEDICAL LTD / DRTS FAQ

What is the fundamental rating for DRTS stock?

ChartMill assigns a fundamental rating of 2 / 10 to DRTS.


Can you provide the valuation status for ALPHA TAU MEDICAL LTD?

ChartMill assigns a valuation rating of 1 / 10 to ALPHA TAU MEDICAL LTD (DRTS). This can be considered as Overvalued.


What is the profitability of DRTS stock?

ALPHA TAU MEDICAL LTD (DRTS) has a profitability rating of 1 / 10.